Karachi: Liven Pharma Limited has disclosed the execution of a share transaction by a non-executive director, Ali Hussain Siddique, in accordance with the Pakistan Stock Exchange (PSX) Regulation 5.6.4. The disclosure, dated December 11, 2025, details the transaction involving a total of 1,000 shares.

According to information available from the Pakistan Stock Exchange (PSX), Ali Hussain Siddique executed the transaction on December 8, 2025, in the ready market. The shares were traded at a rate of 53.2939766651, bringing the cumulative number of shares held to 42.74.

The disclosure notes that such transactions by directors, CEOs, executives, substantial shareholders, their spouses, and minors must be presented by the company secretary at the subsequent Board of Directors meeting. It is mandated that extracts of the minutes are submitted via Form-30 of the Correspondence Manual through PUCARS.

Furthermore, the regulation ensures that the holding period for these transactions is over six months. If any transaction occurs within this period, a cheque equivalent to the profit must be deposited with the Securities and Exchange Commission of Pakistan (SECP), as stipulated by Section 105 of the Securities Act, 2015, with intimation to PSX.

Liven Pharma Limited is required to update the details of the transaction in the UIN Management System immediately. The regulation also prohibits directors, CEOs, or executives from dealing in the shares of the listed company during a closed period.